|
An open-label, pharmacokinetic study to determine the bioavailability, safety and tolerability of single dose oral docetaxel in metastatic prostate cancer (mPC) patients treated with IV docetaxel. |
|
Christopher G. C. A. Jackson |
Honoraria - Athenex; MSD Oncology |
Research Funding - Athenex (Inst) |
Patents, Royalties, Other Intellectual Property - Patent pending - Oraxol - Athenex. No financial interest. |
Travel, Accommodations, Expenses - Athenex |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Athenex; Merck Sharp & Dohme |
|
|
|
Stock and Other Ownership Interests - Athenex |
|
|
|
Stock and Other Ownership Interests - Athenex; Gilead Sciences |
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - Athenex; GlaxoSmithKline; Merck/Schering Plough |
Patents, Royalties, Other Intellectual Property - Multiple patents hold as employee of Athenex Inc, no royalties from any. |
Travel, Accommodations, Expenses - Athenex |
|
|
No Relationships to Disclose |